JP7275104B2 - 遺伝子操作された細胞の組成物および関連組成物を産生するための方法 - Google Patents

遺伝子操作された細胞の組成物および関連組成物を産生するための方法 Download PDF

Info

Publication number
JP7275104B2
JP7275104B2 JP2020506936A JP2020506936A JP7275104B2 JP 7275104 B2 JP7275104 B2 JP 7275104B2 JP 2020506936 A JP2020506936 A JP 2020506936A JP 2020506936 A JP2020506936 A JP 2020506936A JP 7275104 B2 JP7275104 B2 JP 7275104B2
Authority
JP
Japan
Prior art keywords
cells
ccr7
composition
ratio
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020506936A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020532954A (ja
JP2020532954A5 (https=
Inventor
ミルナ ムヤチッチ
アユ ラハルジョ
Original Assignee
ジュノー セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジュノー セラピューティクス インコーポレイテッド filed Critical ジュノー セラピューティクス インコーポレイテッド
Publication of JP2020532954A publication Critical patent/JP2020532954A/ja
Publication of JP2020532954A5 publication Critical patent/JP2020532954A5/ja
Priority to JP2022127886A priority Critical patent/JP2022160657A/ja
Application granted granted Critical
Publication of JP7275104B2 publication Critical patent/JP7275104B2/ja
Priority to JP2025005308A priority patent/JP2025063189A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1114—T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70514—CD4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70517—CD8

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
JP2020506936A 2017-08-09 2018-08-09 遺伝子操作された細胞の組成物および関連組成物を産生するための方法 Active JP7275104B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022127886A JP2022160657A (ja) 2017-08-09 2022-08-10 遺伝子操作された細胞の組成物および関連組成物を産生するための方法
JP2025005308A JP2025063189A (ja) 2017-08-09 2025-01-15 遺伝子操作された細胞の組成物および関連組成物を産生するための方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762543363P 2017-08-09 2017-08-09
US62/543,363 2017-08-09
US201762596770P 2017-12-08 2017-12-08
US62/596,770 2017-12-08
PCT/US2018/046149 WO2019032927A1 (en) 2017-08-09 2018-08-09 METHODS FOR PRODUCING GENETICALLY MODIFIED CELL COMPOSITIONS AND COMPOSITIONS THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022127886A Division JP2022160657A (ja) 2017-08-09 2022-08-10 遺伝子操作された細胞の組成物および関連組成物を産生するための方法

Publications (3)

Publication Number Publication Date
JP2020532954A JP2020532954A (ja) 2020-11-19
JP2020532954A5 JP2020532954A5 (https=) 2021-09-16
JP7275104B2 true JP7275104B2 (ja) 2023-05-17

Family

ID=63405421

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020506936A Active JP7275104B2 (ja) 2017-08-09 2018-08-09 遺伝子操作された細胞の組成物および関連組成物を産生するための方法
JP2022127886A Withdrawn JP2022160657A (ja) 2017-08-09 2022-08-10 遺伝子操作された細胞の組成物および関連組成物を産生するための方法
JP2025005308A Pending JP2025063189A (ja) 2017-08-09 2025-01-15 遺伝子操作された細胞の組成物および関連組成物を産生するための方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022127886A Withdrawn JP2022160657A (ja) 2017-08-09 2022-08-10 遺伝子操作された細胞の組成物および関連組成物を産生するための方法
JP2025005308A Pending JP2025063189A (ja) 2017-08-09 2025-01-15 遺伝子操作された細胞の組成物および関連組成物を産生するための方法

Country Status (12)

Country Link
US (3) US11851678B2 (https=)
EP (1) EP3664820B1 (https=)
JP (3) JP7275104B2 (https=)
KR (2) KR102755437B1 (https=)
CN (1) CN111246862B (https=)
AU (1) AU2018313950A1 (https=)
BR (1) BR112020001605A2 (https=)
CA (1) CA3070579A1 (https=)
ES (1) ES2959953T3 (https=)
MA (1) MA49979A (https=)
MX (1) MX2020001490A (https=)
WO (1) WO2019032927A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018275894B2 (en) 2017-06-02 2025-04-24 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
AU2018313950A1 (en) 2017-08-09 2020-02-13 Juno Therapeutics, Inc. Methods for producing genetically engineered cell compositions and related compositions
EP3704230B1 (en) 2017-11-01 2024-10-23 Juno Therapeutics, Inc. Process for generating therapeutic compositions of engineered cells
CA3084446A1 (en) * 2017-12-08 2019-06-13 Juno Therapeutics, Inc. Phenotypic markers for cell therapy and related methods
JP7433230B2 (ja) 2017-12-08 2024-02-19 ジュノー セラピューティクス インコーポレイテッド 細胞を培養するための無血清培地配合物およびその使用の方法
CN113474450A (zh) * 2018-08-09 2021-10-01 朱诺治疗学股份有限公司 产生工程化细胞的方法以及所述工程化细胞的组合物
EP3874024A1 (en) 2018-10-31 2021-09-08 Juno Therapeutics GmbH Methods for selection and stimulation of cells and apparatus for same
WO2021004400A1 (zh) * 2019-07-06 2021-01-14 苏州克睿基因生物科技有限公司 一种表达cd3抗体受体复合物的免疫细胞及其用途
KR20220122656A (ko) 2019-12-06 2022-09-02 주노 쎄러퓨티크스 인코퍼레이티드 Ｇｐｒｃ5ｄ-표적화 결합 도메인에 대한 항-이디오타입 항체 및 관련 조성물 및 방법
US20240182920A1 (en) * 2020-01-22 2024-06-06 Carsgen Therapeutics Co., Ltd. Method for transducing cells with viral vector
IL295381B1 (en) * 2020-02-12 2026-04-01 Juno Therapeutics Inc BCMA-directed chimeric T-cell antigen receptor compounds and methods and uses thereof
AU2021219886B2 (en) * 2020-02-13 2025-01-23 Imunopharm Technology Co., Ltd. Optimization of chimeric antigen receptor
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
CN121464348A (zh) * 2023-05-23 2026-02-03 朱诺治疗学股份有限公司 T细胞的激活标记物和评估t细胞激活的方法
KR20250074841A (ko) * 2023-11-20 2025-05-28 (재) 스크립스코리아항체연구원 키메라 항원 수용체를 발현하는 면역 세포 및 트렙타비딘 스캐폴드 항체 유사 단백질을 포함하는 항암용 조성물, 및 이의 용도

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014510108A (ja) 2011-03-23 2014-04-24 フレッド ハッチンソン キャンサー リサーチ センター 細胞免疫療法のための方法および組成物
JP2014509841A (ja) 2011-01-18 2014-04-24 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 癌を治療するための組成物および方法

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
ES2067018T3 (es) 1988-12-28 1995-03-16 Stefan Miltenyi Procedimiento y materiales para la separacion en alto gradiente magnetico de materiales biologicos.
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
CA2096222C (en) 1990-11-13 1998-12-29 Stephen D. Lupton Bifunctional selectable fusion genes
WO1994028143A1 (en) 1993-05-21 1994-12-08 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
WO1996013593A2 (en) 1994-10-26 1996-05-09 Procept, Inc. Soluble single chain t cell receptors
WO1996018105A1 (en) 1994-12-06 1996-06-13 The President And Fellows Of Harvard College Single chain t-cell receptor
US20020150914A1 (en) 1995-06-30 2002-10-17 Kobenhavns Universitet Recombinant antibodies from a phage display library, directed against a peptide-MHC complex
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5773224A (en) 1996-02-12 1998-06-30 Grandics; Peter Immunoselection system for cell elution
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
WO1997034634A1 (en) 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Single chain fv constructs of anti-ganglioside gd2 antibodies
WO1999018129A1 (en) 1997-10-02 1999-04-15 Sunol Molecular Corporation Soluble single-chain t-cell receptor proteins
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
RU2149023C1 (ru) 1998-04-20 2000-05-20 Ерхов Валентин Сергеевич Способ получения специфической антисыворотки к универсальному опухолевому антигену и способ диагностики злокачественных опухолей с использованием этой антисыворотки
WO1999060120A2 (en) 1998-05-19 1999-11-25 Avidex Limited Soluble t cell receptor
JP2002524081A (ja) 1998-09-04 2002-08-06 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ 前立腺−特異的膜抗原に特異的な融合受容体およびその使用
WO2000023573A2 (en) 1998-10-20 2000-04-27 City Of Hope Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies
WO2000043551A1 (en) 1999-01-26 2000-07-27 Cornell Research Foundation, Inc. Determining viral load in double negative t cells
US20030235908A1 (en) 2000-02-24 2003-12-25 Xcyte Therapies, Inc. Activation and expansion of cells
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US20020131960A1 (en) 2000-06-02 2002-09-19 Michel Sadelain Artificial antigen presenting cells and methods of use thereof
AU2001297703B2 (en) 2000-11-07 2006-10-19 City Of Hope CD19-specific redirected immune cells
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
AU2002321581C1 (en) 2001-08-31 2008-09-18 Adaptimmune Limited Soluble T cell receptor
US7939059B2 (en) 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
AU2003216341A1 (en) 2002-02-20 2003-09-09 Dyax Corporation Mhc-peptide complex binding ligands
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
SI1545613T1 (sl) 2002-07-31 2011-11-30 Seattle Genetics Inc Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni
CA2500392C (en) 2002-09-27 2012-11-27 The General Hospital Corporation Microfluidic device for cell separation and uses thereof
AU2003271904B2 (en) 2002-10-09 2009-03-05 Adaptimmune Limited Single chain recombinant T cell receptors
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
CA2565581C (en) 2003-05-02 2014-07-08 Insception Bioscience, Inc. Apparatus and methods for amplification of blood stem cell numbers
AU2005247950B2 (en) 2004-05-27 2012-02-02 Receptor Logic, Inc. Antibodies as T cell receptor mimics, methods of production and uses thereof
US20090304679A1 (en) 2004-05-27 2009-12-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
US20090226474A1 (en) 2004-05-27 2009-09-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
US8361794B2 (en) 2004-06-29 2013-01-29 Immunocore Limited Cells expressing a modified T cell receptor
US20090208471A1 (en) 2006-04-07 2009-08-20 Yun Theodore J Isolation and Use of Human Regulatory T Cells
US20080085532A1 (en) 2006-09-18 2008-04-10 Jorn Gorlach Method for determining the immune status of a subject
CA2682527C (en) 2007-03-30 2017-07-11 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes
EP3620465B1 (en) 2007-07-03 2025-02-19 Dako Denmark A/S Improved methods for generation, labeling and use of mhc multimers
WO2009072003A2 (en) 2007-12-07 2009-06-11 Miltenyi Biotec Gmbh Sample processing system and methods
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
RS56844B1 (sr) 2007-12-11 2018-04-30 Univ North Carolina Chapel Hill Retrovirusni vektori sa modifikovanim polipurinskim nizom
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
US20110070581A1 (en) 2009-04-27 2011-03-24 Amit Gupta Separation of Leukocytes
CA2777053A1 (en) 2009-10-06 2011-04-14 The Board Of Trustees Of The University Of Illinois Human single-chain t cell receptors
DK2496698T3 (en) 2009-11-03 2019-04-15 Hope City TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (EGFRt) FOR TRUNCATED T-CELL SELECTION
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
KR20140033029A (ko) 2011-04-01 2014-03-17 메모리얼 슬로안-케터링 캔서 센터 에이치엘에이 에이2에 의해 제공된 더블유티1 펩타이드에 특이적인 티 세포 수용체 유사 항체
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
DK2726600T3 (en) 2011-07-01 2017-05-15 Amgen Inc Mammalian Cell Culture
TR201811128T4 (tr) 2011-07-18 2018-08-27 Iba Gmbh Bir hedef hücrenin tersinir şekilde boyama yöntemi.
WO2013038272A2 (en) 2011-09-13 2013-03-21 Uti Limited Partnership Streptavidin mutein exhibiting reversible binding for biotin and streptavidin binding peptide tagged proteins
WO2013062365A2 (ko) 2011-10-26 2013-05-02 국립암센터 변이 ｃｔｌａ4 유전자 이입 ｔ 세포 및 이를 포함하는 항암 면역치료용 조성물
KR102134932B1 (ko) 2011-11-11 2020-07-17 프레드 헛친슨 켄서 리서치 센터 암을 위한 사이클린 ａ１―표적화된 ｔ―세포 면역요법
JP6850528B2 (ja) 2012-02-13 2021-03-31 シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート 二重特異性キメラ抗原受容体およびその治療的使用
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
RU2746407C1 (ru) 2012-02-23 2021-04-13 Стейдж Селл Терапеутикс Гмбх Хроматографическое выделение клеток и других сложных биологических материалов
SG10201609210SA (en) 2012-05-03 2016-12-29 Hutchinson Fred Cancer Res Enhanced affinity t cell receptors and methods for making the same
AU2013289979A1 (en) 2012-07-13 2015-01-22 The Trustees Of The University Of Pennsylvania Methods of assessing the suitability of transduced T cells for administration
CA2881981A1 (en) 2012-08-20 2014-02-27 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
AU2013327136A1 (en) 2012-10-02 2015-04-16 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
DE112012007250B4 (de) 2012-12-20 2024-10-24 Mitsubishi Electric Corp. Fahrzeuginterne Vorrichtung und Programm
DK2958943T3 (da) 2013-02-20 2019-12-09 Univ Pennsylvania Behandling af cancer ved anvendelse af humaniseret anti-EGFRvIII kimær antigenreceptor
CN103305464B (zh) 2013-06-05 2015-04-15 南昌大学 直接分离cd4+和cd8+淋巴细胞的方法
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
AU2015244039B2 (en) 2014-04-07 2021-10-21 Novartis Ag Treatment of cancer using anti-CD19 chimeric antigen receptor
RU2763795C2 (ru) 2014-04-23 2022-01-11 Джуно Терапьютикс, Инк. Способы выделения, культивирования и генетической инженерии популяций клеток иммунной системы для адоптивной терапии
NZ725201A (en) 2014-04-25 2018-05-25 Bluebird Bio Inc Improved methods for manufacturing adoptive cell therapies
DK3166968T3 (da) 2014-05-02 2021-12-06 Univ Pennsylvania Sammensætninger og fremgangsmåder til kimæriske autoantistofreceptor-T-celler
AU2015289644A1 (en) * 2014-07-15 2017-02-02 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
ES2781175T3 (es) 2014-07-31 2020-08-31 Novartis Ag Subconjunto optimizado de células T que contienen un receptor de antígeno quimérico
TWI805109B (zh) 2014-08-28 2023-06-11 美商奇諾治療有限公司 對cd19具專一性之抗體及嵌合抗原受體
CA2969456A1 (en) 2014-12-03 2016-06-09 Juno Therapeutics, Inc. Methods and compositions for adoptive cell therapy
SI3227339T1 (sl) 2014-12-05 2022-02-28 Memorial Sloan-Kettering Cancer Center Himerni antigenski receptorji, ki ciljajo na receptor, povezan z G-proteinom, in njihova uporaba
AU2015357526B2 (en) 2014-12-05 2022-03-17 Eureka Therapeutics, Inc. Chimeric antigen receptors targeting B-cell maturation antigen and uses thereof
EP3227324A4 (en) 2014-12-05 2018-08-29 Memorial Sloan Kettering Cancer Center Antibodies targeting g-protein coupled receptor and methods of use
KR20240135036A (ko) 2014-12-05 2024-09-10 메모리얼 슬로안 케터링 캔서 센터 B-세포 성숙화 항원을 표적화하는 항체 및 사용 방법
JP6597638B2 (ja) 2014-12-22 2019-10-30 富士フイルム和光純薬株式会社 ビオチン化核酸の分離方法
US20180140602A1 (en) 2015-04-07 2018-05-24 Novartis Ag Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
MX2017012939A (es) 2015-04-08 2018-05-22 Novartis Ag Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
AU2016297014B2 (en) * 2015-07-21 2021-06-17 Novartis Ag Methods for improving the efficacy and expansion of immune cells
SG11201803330WA (en) 2015-10-22 2018-05-30 Juno Therapeutics Gmbh Methods for culturing cells and kits and apparatus for same
MX2018005274A (es) 2015-10-30 2019-09-19 The Regents Of The Universtiy Of California Metodos para la generacion de celulas-t a partir de celulas madre y metodos inmunoterapeuticos que utilizan las celulas-t.
US12163952B2 (en) 2017-02-27 2024-12-10 Juno Therapeutics, Inc. Determining toxicity risk in CAR T-cell therapy
CN111263641B (zh) 2017-08-09 2025-10-31 朱诺治疗学股份有限公司 用于制备基因工程化细胞的方法和组合物
AU2018313950A1 (en) 2017-08-09 2020-02-13 Juno Therapeutics, Inc. Methods for producing genetically engineered cell compositions and related compositions
WO2019113557A1 (en) 2017-12-08 2019-06-13 Juno Therapeutics, Inc. Process for producing a composition of engineered t cells
CA3084446A1 (en) 2017-12-08 2019-06-13 Juno Therapeutics, Inc. Phenotypic markers for cell therapy and related methods

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014509841A (ja) 2011-01-18 2014-04-24 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 癌を治療するための組成物および方法
JP2014510108A (ja) 2011-03-23 2014-04-24 フレッド ハッチンソン キャンサー リサーチ センター 細胞免疫療法のための方法および組成物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GARDNER, Rebecca A. et al.，Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults，Blood，米国，The American Society of Hematology，2017年04月13日，Vol.129, No.25，pp.3322-3331, supplemental methods

Also Published As

Publication number Publication date
CN111246862B (zh) 2026-01-13
BR112020001605A2 (pt) 2020-08-11
EP3664820A1 (en) 2020-06-17
CN111246862A (zh) 2020-06-05
RU2020109864A (ru) 2021-09-14
JP2020532954A (ja) 2020-11-19
EP3664820B1 (en) 2023-07-19
WO2019032927A1 (en) 2019-02-14
KR20200054178A (ko) 2020-05-19
US12215348B2 (en) 2025-02-04
US20250250541A1 (en) 2025-08-07
US11851678B2 (en) 2023-12-26
KR102755437B1 (ko) 2025-01-20
RU2020109864A3 (https=) 2022-01-10
JP2022160657A (ja) 2022-10-19
US20240076617A1 (en) 2024-03-07
JP2025063189A (ja) 2025-04-15
MX2020001490A (es) 2020-08-06
US20200181575A1 (en) 2020-06-11
ES2959953T3 (es) 2024-02-29
AU2018313950A1 (en) 2020-02-13
MA49979A (fr) 2020-06-17
CA3070579A1 (en) 2019-02-14
KR20250016455A (ko) 2025-02-03

Similar Documents

Publication Publication Date Title
US12215348B2 (en) Methods for producing genetically engineered cell compositions and related compositions
US20240368625A1 (en) Methods and compositions for preparing genetically engineered cells
US20200289565A1 (en) Combination of a cell therapy and a gamma secretase inhibitor
JP2023120386A (ja) Ｔ細胞療法とｂｔｋ阻害剤との併用療法
JP2019536461A (ja) 養子細胞療法のための操作細胞の産生
KR20230159851A (ko) 치료 세포 조성물의 효력을 결정하는 방법
RU2790444C2 (ru) Способы получения композиций генно-инженерных клеток и родственных композиций
RU2795454C2 (ru) Способы и композиции для получения генно-инженерных клеток

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200422

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210806

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210806

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220511

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220810

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220907

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230110

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230110

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20230119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230217

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230220

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230224

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230410

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230502

R150 Certificate of patent or registration of utility model

Ref document number: 7275104

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150